StockData
Kura Oncology, Inc. logo

Kura Oncology, Inc. (KURA) stock

KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$7.34−0.15 (-2.00%)

Close on Nov 18, 2026Market cap $652.97MP/E –Yield –

Earnings

Kura Oncology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 4, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$22.84M
+9.8% on a year earlier
EPS, Q3 FY2026
-$0.78
-$0.85 a year earlier
Latest guidance
Issued
Nov 10, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Kura Oncology's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 4, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026after the close$22.84M+9.8%-$0.78Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026during market hours$20.87M+36.4%-$0.77Release
Q1 FY2026ended Mar 31, 2026May 12, 2026during market hours$18.27M+29.5%-$0.83Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026before the open$17.34M-67.8%-$0.92Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025before the open$20.80M–-$0.85Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours$15.30M––Release
Q1 FY2025ended Mar 31, 2025May 1, 2025during market hours$14.10M–-$0.66Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025during market hours$53.90M––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024during market hours–––Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours––-$0.59Release
Q1 FY2024ended Mar 31, 2024May 2, 2024during market hours––-$0.59Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Kura Oncology's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
collaboration revenueFY2026$40.00M – $45.00M–NewNov 10, 2026
non-cash collaboration revenue recognitionFY2026$45.00M – $55.00M–NewJan 12, 2026
collaboration revenueFY2027$90.00M – $110.00M–NewNov 10, 2026
collaboration revenueFY2028$90.00M – $110.00M–NewNov 10, 2026

Guidance history

Every forecast Kura Oncology put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 10, 2026collaboration revenueFY2026$40.00M – $45.00MNew
Nov 10, 2026collaboration revenueFY2027$90.00M – $110.00MNew
Nov 10, 2026collaboration revenueFY2028$90.00M – $110.00MNew
Jan 12, 2026non-cash collaboration revenue recognitionFY2026$45.00M – $55.00MNew
Nov 4, 2021Operating expensesFY2021$130.00M – $140.00MNew
Nov 4, 2021Net cash used in operating activitiesFY2021$105.00M – $115.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Kura Oncology filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. News
  8. Results
  9. News
  10. News
  11. Results
  12. Results
  13. News
  14. News
  15. Results

See a number that looks wrong?